National Cancer Institute (NCI): Mission, Research, and Resources
The National Cancer Institute is the largest of the 27 institutes and centers that comprise the National Institutes of Health, and it serves as the federal government's principal agency for cancer research and training. This page covers NCI's statutory mission, its operational research structure, the programs it funds, and the distinctions between its intramural and extramural functions. Understanding NCI's scope is essential for researchers, clinicians, patients, and policymakers navigating federal cancer science infrastructure.
Definition and scope
NCI was established by the National Cancer Act of 1937, making it the oldest institute within NIH. Its mandate was significantly expanded by the National Cancer Act of 1971 (Public Law 92-218), signed by President Nixon, which directed the creation of the National Cancer Program and authorized substantially increased federal investment in cancer research. NCI's authorizing statute charges it with conducting and supporting research, training, health information dissemination, and other programs related to the cause, diagnosis, prevention, and treatment of cancer.
NCI's annual budget exceeds $6.9 billion (NIH Budget), representing the largest single-institute allocation within NIH. The institute supports more than 150 cancer centers across the United States through its NCI-Designated Cancer Centers Program, a network that includes 71 Comprehensive Cancer Centers recognized for their depth of research, clinical, and community outreach capabilities (NCI Cancer Centers).
NCI operates under the broader NIH structure described in the NIH institutes and centers list, which catalogs the full organizational landscape of the agency.
How it works
NCI delivers its mission through two parallel research tracks:
Intramural Research Program (IRP)
The NCI IRP is headquartered primarily at the NIH campus in Bethesda, Maryland, and at the Frederick National Laboratory for Cancer Research in Frederick, Maryland — the only federally funded laboratory dedicated exclusively to cancer research. Intramural scientists conduct research using federal appropriations directly, without applying for competitive grants. The NCI IRP houses more than 250 principal investigators across divisions including the Center for Cancer Research and the Division of Cancer Epidemiology and Genetics.
Extramural Research Program
The extramural program funds research performed at universities, medical centers, and other institutions through grants, contracts, and cooperative agreements. This is the larger of the two programs by budget allocation. Extramural mechanisms include:
The distinction between intramural and extramural research has structural implications for how results are produced and disseminated, a topic covered more broadly at NIH intramural vs. extramural research.
Common scenarios
NCI programs intersect with the work of researchers, clinicians, and patients through three primary operational contexts:
Clinical trials activation. NCI funds the largest publicly supported cancer clinical trials infrastructure in the United States. The NCTN coordinates Phase 2 and Phase 3 trials across more than 3,000 sites nationally. Trials are registered and tracked through ClinicalTrials.gov, a registry maintained by the National Library of Medicine. NCI's Cancer Therapy Evaluation Program (CTEP) manages investigational new drug applications for trials using NCI-held INDs.
Cancer center designation review. Institutions seeking NCI designation submit to a competitive peer review process evaluating scientific programs, shared resources, and institutional cancer-relevant funding. Comprehensive designation requires documented evidence of transdisciplinary research programs and community outreach. Designation is not permanent; centers undergo renewal review on a five-year cycle.
Surveillance data use. NCI operates the Surveillance, Epidemiology, and End Results (SEER) program (seer.cancer.gov), which collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 48 percent of the U.S. population. SEER data are the primary federal source for cancer incidence trends, used in epidemiological research, health policy analysis, and clinical guideline development.
Decision boundaries
NCI does not regulate drug approvals, cancer screening mandates, or clinical practice guidelines as binding policy — those functions fall to the Food and Drug Administration and the U.S. Preventive Services Task Force, respectively. NCI's role is to fund, conduct, and disseminate research; it produces evidence that informs regulatory and clinical decisions but does not issue enforceable standards.
A key distinction exists between NCI-Designated Cancer Centers and NCI-funded institutions generally. Designation is a competitive recognition of research infrastructure quality; receiving an NCI grant does not confer designated status, and the two categories should not be conflated. A hospital system may hold active NCI grants without meeting the threshold for designation.
NCI's health information function — primarily through the Cancer.gov portal and the PDQ (Physician Data Query) database — produces peer-reviewed cancer information summaries for clinicians and patients. PDQ summaries are explicitly not clinical practice guidelines; they synthesize evidence and are reviewed by editorial boards, but NCI makes clear that treatment decisions remain with individual clinicians and patients.
For context on how NCI fits within NIH's broader research priorities and resource allocation, the NIH research priorities and initiatives page provides the agency-wide framework. The full scope of NIH's public health mandate is accessible from the NIH authority home.